DRC receives 70,000 Ervebo vaccines to bolster frontline Ebola response

The World Health Organization allocated 70,000 Ervebo Ebola vaccine doses to the Democratic Republic of Congo to bolster the response to what officials describe as the fastest and deadliest Ebola outbreak, with 50,000 doses earmarked for frontline healthcare workers and 20,000 set aside for a Phase III trial to test the vaccine's effectiveness against the Bundibugyo strain currently circulating in eastern DRC. Ervebo is licensed for the Zaire ebolavirus strain, but not for Bundibugyo; early laboratory and animal data suggest there may be some cross-protection, making the upcoming trial crucial for guiding future outbreak responses. The trial is designed to provide reliable clinical data on cross-strain protection to inform vaccination strategies in similar scenarios. The outbreak has surged with thousands of deaths and a rapid transmission pace, overwhelming local health systems and prompting intensified surveillance and response efforts. The allocations come from the global emergency stockpile managed by the International Coordinating Group and involve partners such as WHO, MSF, UNICEF, and the Red Cross movement to support both vaccination and research initiatives.